---
title: "Rufinamide - Lennox-Gastaut Syndrome"
sidebar: mydoc_sidebar
permalink: db06201-mesh-d065768-1.html
toc: false 
---


Path ID: `DB06201_MESH_D065768_1`
{% include image.html url="images/db06201-mesh-d065768-1.png" file="db06201-mesh-d065768-1.png" alt="db06201-mesh-d065768-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:C079703 | rufinamide | Drug |
| UniProt:Q15858 | Sodium channel protein type 9 subunit alpha | Protein |
| GO:0019228 | neuronal action potential | BiologicalProcess |
| GO:0007269 | neurotransmitter secretion | BiologicalProcess |
| HP:0032792 | Tonic seizure | PhenotypicFeature |
| MESH:D065768 | Lennox-Gastaut syndrome | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Rufinamide | DECREASES ACTIVITY OF | Sodium Channel Protein Type 9 Subunit Alpha |
| Sodium Channel Protein Type 9 Subunit Alpha | POSITIVELY REGULATES | Neuronal Action Potential |
| Neuronal Action Potential | POSITIVELY CORRELATED WITH | Neurotransmitter Secretion |
| Neurotransmitter Secretion | POSITIVELY CORRELATED WITH | Tonic Seizure |
| Tonic Seizure | POSITIVELY CORRELATED WITH | Lennox-Gastaut Syndrome |
|---------|-----------|---------|

Reference: 
  - [https://go.drugbank.com/drugs/DB06201#mechanism-of-action](https://go.drugbank.com/drugs/DB06201#mechanism-of-action)
  - [https://en.wikipedia.org/wiki/Rufinamide](https://en.wikipedia.org/wiki/Rufinamide)
  - [https://pubmed.ncbi.nlm.nih.gov/30391662/](https://pubmed.ncbi.nlm.nih.gov/30391662/)
  - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461817/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461817/)
  - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461817/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461817/)
  - [https://en.wikipedia.org/wiki/Lennox%E2%80%93Gastaut_syndrome#Seizures](https://en.wikipedia.org/wiki/Lennox%E2%80%93Gastaut_syndrome#Seizures)
